Skip to content

Diagnostic efficacy and safety of transesophageal endoscopic ultrasound with bronchoscope-guided fine needle aspiration (EUS-B-FNA) for the patients with lung cancer with respiratory failure

Diagnostic efficacy and safety of transesophageal endoscopic ultrasound with bronchoscope-guided fine needle aspiration (EUS-B-FNA) for the patients with lung cancer with respiratory failure - Diagnostic efficacy and safety of transesophageal endoscopic ultrasound with bronchoscope-guided fine needle aspiration (EUS-B-FNA) for the patients with lung cancer with respiratory failure

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000041235
Enrollment
30
Registered
2020-07-28
Start date
2020-07-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Sponsors

Third department of internal medicine, Universtiy of Fukui
Lead Sponsor
Japanese Red Cross Fukui Hospital, Municipal Tsuruga Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patients with suspicion of lung cacner on radiological examinations. 2. Patiants who have a lesion adjacent to esophagus which is accessible by EUS-B-FNA. 3. Patients who need oxygen therapy to maintain oxygen saturation (90%), whose condition make it impossible or difficult to perform bronchoscopy because of respiratory comorbidity, or who have poor ECOG-PS (2 or more).

Exclusion criteria

Exclusion criteria: 1. Patients with esophageal varices or coagulation disorder. 2. Pregnant woman.

Design outcomes

Primary

MeasureTime frame
Diagnostic yeild and safety of EUS-B-FNA.

Secondary

MeasureTime frame
Ratio of evaluable samples by the PD-L1 immunohistochemistry. Ratio of evaluable samples of oncogene mutation status (EGFR, ROS1, ALK, and BRAF). Overall survival. Overall survival stratified by existence of driver oncogene or tumor PD-L1 expression.

Countries

Japan

Contacts

Public ContactYukihiro Umeda

University of Fukui Third department of internal medicine

umeda@u-fukui.ac.jp0776613111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026